Dx dialogues: pharmacologic advances for the treatment and management of schizophrenia
Ragy Girgis, MD, walks through the advances we've seen in pharmacologic approaches for the treatment and management of schizophrenia.
Up Next
Dx dialogues: identifying patients who might benefit from an LAI for schizophrenia
Dx dialogues: stigma surrounding LAI use for schizophrenia and the importance of patient education
Dx dialogues: why early intervention is critical in managing tardive dyskinesia
Dx dialogues: the challenges of treating tardive dyskinesia the "old-fashioned way"
Dx dialogues: VMAT2 inhibitors and future treatments for tardive dyskinesia
Caring for patients with schizophrenia and other psychiatric disorders
A caregiver's guide to schizophrenia medications
Dx dialogues: considerations when deciding whether to initiate pharmacologic interventions for patients with AD
Dx dialogues: novel approaches in development for the treatment of AD
Dx dialogues: recent advancements and implementation strategies in opioid use disorder treatment
